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Abstract
Among bacterial foodborne pathogens, non-typhoid Salmonella enterica (NTS) is a leading cause of death worldwide. This study assessed
short-term and long-term mortality following NTS infection in Israel, and evaluated the effects of age, sex, source of isolation and differ-
ent serotypes on mortality. The source of data was a national registry of NTS isolates submitted to the Salmonella Reference Center,
Government Central Laboratories, in Jerusalem, Israel, during 1997–2006. Vital status was derived from the registry of the Israeli Minis-
try of the Interior. The survival of a cohort of 15 919 patients infected with the top ﬁve NTS serotypes was evaluated by calculating
age-standardized mortality ratios (SMRs) and by Cox proportional hazards multivariate regressions at three follow-up time intervals:
30 days, 1 year and end of follow-up. The median follow-up time was 6.44 years (mean, 6.21 years; range, 1 day to 10.80 years). The
cumulative crude mortality rates at the three time intervals were 0.68%, 1.86% and 4.40%, respectively, corresponding to increased
SMRs of 16.95 (95% CI 13.9–20.46), 4.25 (95% CI 3.78–4.76), and 1.83 (95% CI 1.70–1.97), respectively. Cox regressions revealed that
increasing age, extraintestinal source of isolation and NTS serotype had signiﬁcant effects on mortality within all three follow-up inter-
vals. The risk of mortality was increased for serotypes Infantis and Typhimurium, and decreased for serotypes Virchow and Hadar, as
compared with serotype Enteritidis. The study revealed curtailed short-term and long-term survival following NTS infection that
persisted for many years following detection by culture.
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Introduction
Non-typhoid Salmonella enterica (NTS) is a predominant
cause of foodborne illnesses worldwide. The majority of
cases present as self-limited gastroenteritis; however, up to
8% of these illnesses may be invasive, and present as bacter-
aemia or other forms of extraintestinal infection [1]. Death
occurs in <1% of infected patients; however, as Salmonella
illnesses are common, the impact on public health is consid-
erable [2–5]. In the USA and the UK, salmonellae are leading
causes of death among patients with foodborne bacterial
infections [2,3].
The well-deﬁned risk factors for adverse outcome include
patient age [6–10], presence of underlying disease, particu-
larly defects in cellular immunity [5,8,10,11], and the pres-
ence of bacteraemia or other invasive disease [7,12].
Infection by a drug-resistant Salmonella strain has also been
associated with increased mortality [13]. Less is known
about long-term survival following NTS infection. Studies
from Denmark have shown that mortality at 1 year is 2.9-
fold higher than that of the general population, after adjust-
ment for underlying illnesses [14].
In Israel, NTS illnesses constitute an important challenge
to health authorities [15]. This is because of the high inci-
dence of NTS in Israel, which was of the order of 50 per
100 000 population in 2003 [15], as compared with 13.4 per
100 000 in the USA [4] and 31.1 per 100 000 in the Euro-
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pean Union [16]. Another important and unique trend in
Israel is the predominance of serotype Virchow, which
emerged in the late 1980s, and during the study years has
become the second most prevalent serotype, accounting for
15–16% of all stool isolates and 22–27% of all blood isolates
[15,17,18]. However, except for selected case series, mortal-
ity due to salmonellosis has not been studied in this country
[10,19]. The aim of the study was to assess the impact
of NTS illnesses on patient survival using a large national
database of laboratory-conﬁrmed cases.
Materials and Methods
Source of data: Salmonella registry
Salmonellosis is a reportable disease in Israel. Cases of sal-
monellosis submitted to the Salmonella Reference Center,
Government Central Laboratories, Israel Ministry of
Health, Jerusalem, between 1 January 1997 and 31 Decem-
ber 2006, formed the source population for the study.
Human Salmonella isolates from all sources are submitted
passively by all clinical microbiology laboratories around
the country to the Salmonella Reference Center, where
ﬁnal serological identiﬁcation has been performed accord-
ing to the Kauffmann–White scheme for the last 60 years
[20]. A patient’s record includes: name, ID number, age,
the date and source of Salmonella isolation and the identi-
ﬁed serotype name.
Study cohort and vital status determination
During the years 1997–2006, the Salmonella Reference Cen-
ter conﬁrmed Salmonella species and performed serotype
identiﬁcation for 40 018 submitted patient isolates. ID num-
bers were available for 32 399 patients. Patient ID and
demographic data were matched with the registry of the
Israeli Ministry of the Interior to retrieve the exact date of
birth, sex and vital status by 18 October 2007. For patients
who died, the date of death was provided.
A match could be veriﬁed for 25 975 patients. The rea-
sons for match failure were incomplete or incorrect entry
of ID number or patient name. Patients with more than
one isolate (with the same serotype) within 12 months
were counted only once, using the earliest date of isola-
tion. Patients with relapse of salmonellosis beyond
12 months and those who were infected with more than
one NTS serotype were excluded. The sources of Salmo-
nella isolation were categorized into stool and extraintesti-
nal sources (all sources that were not stool). Patients who
had Salmonella isolated from both stool and an extraintes-
tinal source were counted only once and categorized as
having an extraintestinal source. The earliest date of isola-
tion was used.
After exclusion of patients with relapse and patients with
multiple Salmonella serotypes, there remained 23 138 cases
of salmonellosis caused by 180 different NTS serotypes. Five
serotypes, Enteritidis, Virchow, Typhimurium, Hadar and
Infantis, were responsible for 69% of the illnesses (15 919
cases) and for 73% of death events (700). The 15 919
patients with NTS infection caused by the top ﬁve serotypes
were included in the study cohort and were followed for
vital status from the time of culture positivity until death or
18 October 2007, whichever occurred ﬁrst.
Statistical analysis
Three follow-up endpoints were selected to assess short-
term and long-term survival intervals: 30 days, 1 year and end
of follow-up time. The data were analysed in three steps. In
the ﬁrst step, the overall and sex-speciﬁc, age-standardized
mortality ratios (SMRs) were calculated using the PAMCOMP
program [21], to compare mortality in the studied population
and that in the general Israeli population. Person-months at
risk were calculated from the reported onset of the disease
until either death or 18 October 2007, whichever occurred
ﬁrst. SMRs were calculated by dividing the observed number
of deaths by the number of expected deaths in the general
population. The expected deaths were calculated by multiply-
ing person-months at risk by the national death rates, for the
same age and sex categories in the years 2000–2001 (study
period average) derived from the Israeli Bureau of Statistics
(which can be accessed at http://www1.cbs.gov.il/reader/shn-
atonenew_site.htm). Analyses were repeated for all three fol-
low-up endpoints. In the second step, Kaplan–Meier survival
curves were constructed to compare mortality between
patients with different categories of age, sex, source of NTS
isolation and NTS serotypes. In the third step, Cox propor-
tional hazards multivariate regressions were constructed for
the estimation of the hazard ratios (HRs) of age, sex, source
of NTS isolation and NTS serotype associated with mortality.
Analyses were repeated for all three follow-up intervals. SPSS
version 16 (SPSS Inc., Chicago, Il, USA) was used for the anal-
yses. All p-values are two-sided.
Ethics considerations
The study was approved by the local Ethics Committee of
the Assaf Harofeh Medical Center, Zeriﬁn, Israel. Special
permission for patient data matching for vital status was
granted by the Ministry of Health legal counsellor. For pur-
poses of conﬁdentiality, after the match, each patient was
given a unique number, and the actual name and ID number
were erased.
CMI Weinberger et al. Curtailed survival following Salmonella infection 279
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 278–284
Results
The study cohort included 8269 males and 7650 females,
with a median age of 3.06 years (mean, 15.47 ± 23.05 years;
range, 1 day to 104 years). The median patient follow-up
time was 6.44 years (mean, 6.21 ± 2.70 years; range, 1 day
to 3942 days or 10.80 years).
Relative mortality in comparison with the general population
One hundred and nine (0.68%) patients died within 30 days,
297 (1.86%) within 1 year, and 700 (4.40%) by the end of
the follow-up time. After exclusion of four patients who
were older than 100 years, comparison with the general
population yielded highly signiﬁcant increased age-adjusted
mortality, for the whole group as well as for each sex, within
the time to follow-up endpoints in all cases (Table 1). SMRs
were highest within 30 days following NTS isolation and low-
est by the end of the follow-up time. For the whole cohort,
the SMRs decreased from 16.95 (95% CI 13.91–20.46) within
30 days, to 4.25 (95% CI 3.78–4.76) within 1 year, to 1.83
(95% CI 1.70–1.97) by the end of the follow-up time.
Kaplan–Meier survival estimates.
Figure 1 presents Kaplan–Meier survival curves extending to
the end of the follow-up period for different categories of age
(Fig. 1a), sex (Fig. 1b), source of NTS isolation (Fig. 1c) and
NTS serotype (Fig. 1d). The log-rank tests yielded signiﬁcant
effects of age (p <0.001) and source of NTS isolation
(p <0.001), and non-signiﬁcant effects of sex (p 0.14) and NTS
serotype (p 0.57).
Effects of age, sex, source of isolation and serotypes
Table 2 presents the adjusted HRs of age, sex, source of
NTS isolation (extraintestinal vs. stool) and NTS serotypes
on mortality within the three follow-up intervals. The
adjusted HRs of age for mortality were highly signiﬁcant
(p <0.001). Patients who were 75 years and older had the
highest risk within all three follow-up intervals (Table 2). For
each age group, the adjusted HRs for mortality increased
with increasing follow-up time. For example, the adjusted
HRs in patients 75 years or older as compared with patients
younger than 20 years increased from 81.31 (95% CI 33.80–
195.59) within 30 days, to 137.00 (95% CI 79.42–236.32)
within 1 year, to 282.51 (95% CI 194.33–410.69) by the end
of the follow-up time (Table 2). The only difference among
sexes was found at the end of the follow-up time after
adjustment for the other variables; males had a slightly higher
adjusted risk than females (HR 1.19, 95% CI 1.03–1.39,
p 0.02) (Table 2).
NTS was isolated from extraintestinal sources in 3.3% of
the whole study cohort, and in 3.5%, 4.5%, 3.0%, 1.7% and
2.4%, respectively, of patients with serotypes Enteritidis, Vir-
chow, Typhimurium, Hadar and Infantis. The adjusted HRs of
the NTS source for mortality were signiﬁcant (p <0.001)
within all three follow-up intervals. Patients with an extrain-
testinal source of Salmonella had signiﬁcantly higher HRs than
those in whom stool was the only source (Table 2). Adjusted
HRs for mortality decreased by approximately 50% with
increasing follow-up time intervals, from 12.12 (95% CI 7.86–
18.71) within 30 days, to 6.23 (95% CI 4.86–8.00) within
1 year, to 3.76 (95% CI 3.16–4.48) by the end of the follow-
up time.
The adjusted HRs of the NTS serotype for mortality were
signiﬁcant at the three follow-up intervals (Table 2). There
was an increased mortality risk with serotypes Infantis and
Typhimurium, and a decreased mortality risk with serotypes
Virchow and Hadar, as compared with serotype Enteritidis.
Discussion
The study revealed that patients with NTS infection due to
the most frequent serotypes in Israel, i.e. Enteritidis, Vir-
chow, Typhimurium, Hadar and Infantis, had curtailed short-
term and long-term survival as compared with the general
Israeli population. These ﬁndings were based on data from a
large laboratory-based national database, collected over a
10-year period (1997–2006), with a follow-up time of up to
10.8 years (mean, 6.2 years). Excess mortality as indicated by
SMRs was highest at 30 days following NTS detection in
culture (16.95), but remained signiﬁcant at 1 year (4.25) and
at the end of the follow-up period (1.83).
TABLE 1. Standardized mortality ratios (SMRs) and
95% CIs for Salmonella illnesses stratiﬁed by sex at three
follow-up endpoints, Israel 1997–2006
Follow-up
intervals
Observed
deaths
Expected
deaths
SMRs
(95% CI)
Thirty days
Males 58 3.38 17.14 (13.02–22.16)
Females 50 3.01 16.59 (12.32–12.88)
All 108 6.37 16.95 (13.91–20.46)
One year
Males 152 36.38 4.18 (3.54–4.90)
Females 143 33.23 4.30 (3.63–5.07)
All 295 69.43 4.25 (3.78–4.76)
End of follow-up
Males 354 192.03 1.84 (1.66–2.05)
Females 342 187.69 1.82 (1.63–2.03)
All 696 379.66 1.83 (1.70–1.97)
Note: SMRs, standardized mortality ratios analyses.
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A comparable trend for 30-day and 1-year intervals
was found in two other studies [9,14]. In the ﬁrst, a large
population-based study from Denmark [14], crude SMRs at
30 days and at 1 year were 15.4 and 3.4, respectively. In the sec-
ond study from Sweden, corresponding SMRs were 5.6 and 1.8,
respectively, for patients with domestically acquired NTS [9].
The present study evaluated the effect of age, sex, source
of NTS and Salmonella serotypes on mortality risk. Except
for sex, all of these variables had an impact on both short-
term and long-term mortality up to 10.8 years of follow-up.
Male sex was associated with an increased risk of mortality
only at the end of the follow-up period, and this may reﬂect
the decreased life-expectancy of males in the general popula-
tion. The effect of age increased with increasing follow-up
time intervals, whereas the effect of the NTS source was
maximal within 30 days, and decreased over time.
Other studies have pointed to the important effect of age
on short-term mortality in patients with NTS infections. A
population-based FoodNet active surveillance study concern-
ing the years 1997–1999 [5] indicated an overall case-fatality
rate of 0.6%, which increased to 3.5% among the elderly
(‡60 years). The case-fatality rate was 74-fold higher in the
elderly than in patients <20 years, and eight-fold higher than
in patients aged 20 to <60 years. In a similar epidemiological
study from California [6], the mortality rates in patients aged
‡80 years (6.4%) were 92-fold higher than in patients aged
<17 years and 2.7-fold higher than in patients aged 65–
79 years.
A more recent FoodNet study [12] concerning the period
1996–2006 reported an acute mortality rate of 3.3% in
patients with invasive disease, as compared with 0.2% in
patients with enteric infection and 0.5% in the entire group.
The impact of invasive NTS infection beyond 30 days was
reported in a single Danish study [22]. At 1 year of follow-
up, the mortality rate in hospitalized patients with NTS
bacteraemia was 21.1%, as compared with 8.1% in patients
hospitalized because of NTS without bacteraemia and 0.2%
in non-hospitalized patients with NTS.
Another notable ﬁnding in the present study consisted in
the different effects of the speciﬁc Salmonella serotypes on
mortality. Interestingly, serotype Virchow, with the highest
proportion of extraintestinal isolation, was associated with
lower rates of mortality than serotype Enteritidis during all
time intervals. One possible explanation is that there are dif-
ferences in age-related invasiveness [23]. In a previous study
from Israel, serotype Virchow was the most invasive NTS
(a) (b)
(c) (d)
FIG. 1. Kaplan–Meier survival curves
for different categories of age groups
(a), sex (b), Salmonella isolation source
(c) and Salmonella serotypes (d) for
15 919 patients with Salmonella illnesses,
Israel 1997–2006. The patients were fol-
lowed from 1 January 1997 until 18
October 2007, giving a total of
10.8 years. The results of log-rank tests
were as follows: p <0.001 for differ-
ences between the age groups, p 0.14
for the differences between the two sex
categories, p <0.001 for the differences
between the two source categories, and
p 0.57 for the overall differences
between the serotype categories.
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serotype in young children, but serotypes Enteritidis and
Typhimurium were more invasive in the elderly, who also
have the highest risk of mortality [23]. A recently published
FoodNet-based study [12] also highlighted the variability in
mortality rates in patients infected with the different NTS
serotypes.
Long-term effects of serotypes on mortality were
reported in two studies from Denmark [8,14]. One-year
mortality rates in patients with the two predominant sero-
types, Enteritidis and Typhimurium, were slightly higher than
in patients with other ‘exotic’ serotypes, and substantially
lower than in patients with serotype Dublin. The reasons
for the long-term consequences of NTS infection is not
clear.
Possible explanations include the tendency of Salmonella
to invade, and establish infection in more vulnerable hosts
and the direct effect of infection on the host. NTS infection
may result in late relapses and complications, including endo-
carditis, endovascular infection, osteomyelitis and bowel per-
foration, all of which may signiﬁcantly curtail survival
[1,14,24]. Acute NTS infection may also augment its impact
by worsening the underlying illnesses, similar to the effects
of inﬂuenza [25]. Furthermore, as many as 22.8% of the
patients with documented salmonellosis in the USA required
TABLE 2. Cox proportional haz-
ards regression models for the
effects of age, sex, source of
Salmonella isolation and Salmonella
serotype on mortality at three fol-
low-up endpoints; multivariate
analyses, Israel 1997–2006
Categories
Cumulative
no. of deaths (%) p-value
Adjusted
HR (95% CI)
30-day interval
Age group (years) – <0.001 –
0 to <20 (n = 11781)a 6 (0.051) – 1.00
20 to <55 (n = 2477) 12 (0.48) <0.001 8.27 (3.09–22.11)
55 to <75 (n = 1071) 29 (2.71) <0.001 30.97 (12.62–76.02)
‡75 (n = 590) 62 (10.51) <0.001 81.31 (33.80–195.59)
Sex
Female (n = 7650)a 59 (0.65) – 1.00
Male (n = 8269) 50 (0.71) 0.52 1.13 (0.78–1.66)
Source
Stool (n = 15392)a 41 (0.27) – 1.00
Extraintestinal (n = 527) 68 (12.90) <0.001 12.12 (7.86–18.71)
Salmonella serotype – 0.01 –
Enteritidis (n = 6146)a 52 (0.85) – 1.00
Virchow (n = 3524) 13 (0.37) 0.19 0.66 (0.36–1.22)
Typhimurium (n = 3080) 24 (0.78) 0.25 1.33 (0.82–2.16)
Hadar (n = 2222) 9 (0.41) 0.34 0.71 (0.34–1.45)
Infantis (n = 947) 11 (1.16) 0.01 2.34 (1.21–4.54)
One-year interval
Age group (years) – <0.001 –
0 to <20 (n = 11781)a 15 (0.13) – 1.00
20 to <55 (n = 2477) 38 (1.53) <0.001 11.63 (6.39–21.16)
55 to <75 (n = 1071) 96 (8.96) <0.001 56.23 (32.45–97.45)
‡75 (n = 590) 148 (25.08) <0.001 137.00 (79.42–236.32)
Sex
Female (n = 7650)a 143 (1.87) – 1.00
Male (n = 8269) 154 (1.86) 0.28 1.13 (0.90–1.43)
Source
Stool (n = 15392)a 168 (1.09) – 1.00
Extraintestinal (n = 527) 129 (24.48) <0.001 6.23 (4.86–8.00)
Salmonella serotype – 0.02 –
Enteritidis (n = 6146)a 130 (2.12) – 1.00
Virchow (n = 3524) 53 (1.50) 0.43 0.88 (0.64–1.21)
Typhimurium (n = 3080) 62 (2.01) 0.05 1.35 (0.99–1.82)
Hadar (n = 2222) 32 (1.44) 0.14 0.74 (0.50–1.10)
Infantis (n = 947) 20 (2.11) 0.12 1.46 (0.91–2.35)
End of follow-up interval
Age group (years) – <0.001 –
0 to <20 (n = 11781)a 31 (0.26) – 1.00
20 to <55 (n = 2477) 80 (3.23) <0.001 12.23 (8.07–18.53)
55 to <75 (n = 1071) 240 (22.41) <0.001 88.86 (61.00–129.44)
‡75 (n = 590) 349 (59.15) <0.001 282.51 (194.33–410.69)
Sex
Female (n = 7650)a 344 (4.50) – 1.00
Male (n = 8269) 356 (4.31) 0.02 1.19 (1.03–1.39)
Source
Stool (n = 15392)a 498 (3.24) – 1.00
Extraintestinal (n = 527) 202 (38.33) <0.001 3.76 (3.16–4.48)
Salmonella serotype – 0.02 –
Enteritidis (n = 6146)a 277 (4.51) – 1.00
Virchow (n = 3524) 135 (3.83) 0.24 0.88 (0.72–1.09)
Typhimurium (n = 3080) 124 (4.03) 0.08 1.21 (0.98–1.49)
Hadar (n = 2222) 116 (5.22) 0.83 0.98 (0.78–1.21)
Infantis (n = 947) 48 (5.07) 0.03 1.40 (1.03–1.91)
HR, hazard ratio.
aReference category.
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hospitalization [12], with the potential of being exposed to
nosocomial infections and iatrogenic events [26]. These ﬁnd-
ings may not be unique to NTS. Decreased survival rates at
long-term follow-up were also reported in hospitalized
patients with bacteraemia, West Nile encephalitis and severe
sepsis [27–29].
The strength of the present study lies in the large cohort
of patients with NTS infection derived from a national data-
base, the long follow-up time and the strong validation of
infection (laboratory conﬁrmation) and death events
(national registry). The unique epidemiology in Israel enabled
us to study the effects of ﬁve different NTS serotypes on
mortality. Long-term mortality associated with serotypes Vir-
chow, Hadar and Infantis has not been previously reported.
The main limitation of the study lies in the lack of infor-
mation regarding two confounders: patient comorbidities
[14] and drug resistance [14,30]. In a study from Denmark
[14], crude and comorbidity-adjusted relative mortality risks
in patients with NTS, as compared with the general popula-
tion, differed by approximately 20%. Notably, in the Danish
study, 94% of the 26 974 patients with NTS infection had no
comorbidities.
Another limitation of the present study derives from a
dropout rate of approximately one-third of the patients reg-
istered in the Salmonella Reference Laboratory, owing to
faulty IDs. However, this is assumed to be a random occur-
rence. Additionally, the low fatality rate of NTS disease
might lead to less precise estimations of mortality risks.
The signiﬁcant effect of NTS illnesses on long-term sur-
vival found in this study adds to the substantial burden of
acute infection on the public health. Curtailed short-term
and long-term survival associated with NTS infection empha-
sizes the need for more effective intervention to guarantee
the safety of our food chain.
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